A method of generating an antibody and cellular immune response against a Plasmodium in a primate, comprising administering at least 103 genetically modified live Plasmodium to the primate, wherein the genetically modified live Plasmodium is a species selected from Plasmodium falciparum, Plasmodium vivax, Plasmodium ovale, Plasmodium malariae, Plasmodium knowlesi, Plasmodium coatneyi, Plasmodium cynomolgi, and Plasmodium simium, and wherein the genetically modified live Plasmodium does not produce functional histamine releasing factor (HRF) protein, to thereby induce an antibody and cellular immune response against the Plasmodium in the primate. In some embodiments at least 104 genetically modified live Plasmodium is administered to the primate. An immunogenic composition for administration to a primate, comprising a at least 103 genetically modified live Plasmodium wherein the genetically modified live Plasmodium is a species selected from Plasmodium falciparum, Plasmodium vivax, Plasmodium ovale, Plasmodium malariae, Plasmodium knowlesi, Plasmodium coatneyi, Plasmodium cynomolgi, and Plasmodium simium, and wherein the genetically modified live Plasmodium does not produce functional histamine releasing factor (HRF) protein and at least one pharmaceutically acceptable excipient and/or support. In some embodiments the immunogenic composition comprises at least 103 genetically modified live Plasmodium.La présente invention concerne un procédé de génération dune réponse immunitaire des anticorps et cellulaire contre un Plasmodium chez un primate, comprenant ladministration dau moins 103Plasmodium vivants génétiquement modifiés au primate, le Plasmodium génétiquement modifié étant une espèce sélectionnée parmi Plasmodium falciparum, Plasmodium vivax, Plasmodium ovale, Plasmodium malariae, Plasmodium knowlesi, Plasmodium coatneyi, Plasmodium cynomolgi, et Plasmodium simium, et le Plasmodium vivant génétiquement modifié ne produisant pas de protéine fonctionnelle du facte
